Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

NCT01491841 is registered in ClinicalTrials.gov with Anne Beaven, MD as lead sponsor.

NCT NCT01491841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01491841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Lead sponsor
Anne Beaven, MD
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2011
Completion date
February 17, 2017
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma